Skip to main content

MedPath Trial Home

Organizations News Research

Data Sources:ClinicalTrials.govEU CTRFDAEMANMPATGAHealth CanadaWHO ICTRP

MedPath Trial Home

Search trials. Track pipelines. Understand approvals. With AI-powered intelligence for clinical research.

Product

Clinical Trials
Drug Intelligence
Global Approvals
AI Research
Pricing

Resources

FAQ
Search

Company

News
About
Contact

Legal

Privacy Policy
Terms of Service

Disclaimer: This website provides information retrieval and data analysis services. The content does not constitute medical advice. Eligibility assessments are for reference only and should not replace consultation with qualified healthcare professionals. Data is sourced from public registries and regulatory agencies; MedPath does not guarantee completeness or accuracy. Always verify information with primary sources.

© 2026 MedPath Trial. All rights reserved.

We value your privacy

We use cookies to analyze site traffic and improve your experience. See our Privacy Policy.

法舒克 - NMPA Drug Approval Details

Approvals/NMPA/Rasburicase for injection

Approved

生物制品

Rasburicase for injection

SANOFI-AVENTIS GROUPE🇨🇳 National Medical Products Administration

Approval Date: Dec 3, 2018
Approval ID: 7MaoULoQ5oX
Company: SANOFI-AVENTIS GROUPE
Type: 生物制品

Approval Details

Approval Id: 7MaoULoQ5oX
Approval Number: 国药准字J20180087
Generic Name: 注射用拉布立海
Generic Name En: Rasburicase for injection
Trade Name: 法舒克
Drug Type: 生物制品
Dosage Form: 注射剂
Strength: 1.5mg
Reg Date: 2018-12-03
Company Name: SANOFI-AVENTIS GROUPE
Company Address: 54,rue La Boétie,F-75008 Paris,France
Production Company Name: sanofi s.p.a.
Production Company Address: Via Valcanello 4, 03012 Anagni (FR), Italy
Company Detail Path: /organization/sanofi-aventis-groupe

Approved

Quick Info

Agency

NMPA

Country

🇨🇳

Approval Date

Dec 3, 2018

Approval ID

7MaoULoQ5oX

Type

生物制品

Back to NMPA Approvals